Insights Into Treatment Pathways of Hodgkin Lymphoma
Perspectives of community physicians from across the US on the management of classical Hodgkin lymphoma (cHL) with regard to clinical and nonclinical factors impacting treatment selection
Rocky Mountain Cancer Centers – October 14, 2021
Faculty Chair
John M. Burke, MD
Rocky Mountain Cancer Centers, Colorado Springs, CO, USA
Texas Oncology – October 21, 2021
Faculty Chair
Yair Levy, MD
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA
Cancer Center of Kansas – October 26, 2021
Faculty Chair
John M. Burke, MD
Rocky Mountain Cancer Centers, Colorado Springs, CO, USA
East – October 28, 2021
Faculty Chair
Yair Levy, MD
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA
More Information
- Virtual series
More Information
- Live Meeting
More Information
- Virtual series
More Information
- Virtual series
REPORT SNAPSHOT
- Assess advisors’ current management of cHL
- Gain insights into advisors’ perceptions of available therapies and understanding of data
- Understand impact of pathways and other nonclinical factors that may affect treatment selection
GEOGRAPHIC REPRESENTATION AND CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprised 10–15 medical oncologists
